Ana Veneziani
@anacveneziani
Followers
430
Following
1K
Media
34
Statuses
286
Medical Oncologist, Princess Margaret Cancer Centre @UHN 🇨🇦
Joined August 2019
Thrilled to share our review on the #ovariancancer heterogeneity and its impact on treatment landscape. Huge thanks to the @pmcancercentre gyne department and the incredible editorial team at @NatRevClinOncol
In a Review now published online, Ana Veneziani, Eduardo Gonzalez-Ochoa, Husam Alqaisi, Ainhoa Madariaga, Gita Bhat, Marjan Rouzbahman, Suku Sneha & Amit Oza provide a comprehensive overview on the heterogeneity and treatment landscape of #ovariancancer
https://t.co/CKLnbBanGC
4
7
43
Such an honour to be part of it with this amazing team
Delighted to be the young representative at the #GCIG #pragmatictrial brainstorming session with @anacveneziani With 🔝 chairs Helen Mackey & Ros Glasspool
0
0
6
New online! Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers https://t.co/MxUIKpqRta
0
17
57
Emerging evidence suggests that specific location of a BRCA mutation may influence the effectiveness of PARP inhibitors and Bevacizumab in ovarian cancer
Benefit of olaparib maintenance in 140 patients with ovarian cancer, by BRCA mutation type and site. BRCA1-mutated patients in the RING or BRCT and BRCA2-mutated in the RAD51-BD appear to have the greatest benefit from adjuvant olaparib. #OpenAccess
https://t.co/2Zxo2XXmeA
0
1
0
Adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer. https://t.co/TIaUvqGh2J
@nagustiga
3
15
43
Using premalignant STIC lesions, our team at @pmcancercentre reveal how tumors exploit repetitive elements to induce immune tolerance. Could targeting viral mimicry conditioning enhance immunotherapy?
New Links: Cancer and Immune Evasion🧬 Recent study found that cancer cells without the tumour suppressor protein p53 become more resistant to the body's immune response. A study led by @decarvalho_lab at @UHN’s @pmcancercentre. https://t.co/COkgq1UuxM;
https://t.co/nLSoS26Agn
0
2
8
KEYLYNK-001: PFS benefit seen, but who really benefits? Let’s dive into the data. #OvarianCancer #Immunotherapy #PARPinhibitors #SGO2025
KEYLYNK-001 results presented at #SGO2025, following #ESGO2025, with several post hoc analyses highlighting the need for deeper interpretation. @SGO_org #SGOMtg #gyncsm
0
0
2
Super interesting
Research led by @KeshariLab, a biochemist and bioengineer at MSK, found that immune cells might be reprogrammed to use the body’s fructose — a naturally occurring sugar — as an energy source that supercharges them to fight cancer. Learn more about this research and its potential
0
0
1
Congrats #TeamUHN! Your passion and dedication make UHN a world-class health system. @Newsweek’s 2025 Best Hospitals list ranks UHN: 🥉 No. 3 hospital in the world 🥉 No. 1 publicly-funded hospital in the world 🥉 No. 1 hospital in Canada Learn more: https://t.co/zT1mQbCHpM
3
32
90
Announcing the inaugural inductees into the Princess Margaret Hall of Fame! 🏆 These eight visionary clinicians have dedicated decades to advancing cancer care. (1/2)
4
10
49
The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease. https://t.co/kPup2nCmx3
0
5
7
Rethinking 🤔 control arms in PlatR ovarian cancer 📄 Investigator initiated Phase II trial: Anetumab+Bev vs weekly Taxol +Bev Weekly Taxol+ Bev: mPFS 12.7m, ORR 65% 🧪Role of IL6? @pmcancercentre @StephanieLheur5 @husalq85
https://t.co/7UlyDWArKN
aacrjournals.org
AbstractPurpose:. Mesothelin (MSLN) is highly expressed in high-grade serous/endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody–drug conjugate directed at the MSLN antigen...
2
5
11
👏🏻 Congratulations to @FedericaMartor5 and Giuliana Pavone, former fellows at the IOSI, @EnteOspedaliero for this important publication on a high unmet need in ovarian cancer 💪🏻Still a lot to do for our patients but promising new drugs are underway https://t.co/AO4gZPVJaa
0
7
33
Proud of our amazing Marcely Bonatto and other Brazilian colleagues who conducted this important study to reduce cardiotoxicity risk in pts receiving doxorubicin #AHA24
Sacubitril-Valsartan effective in reducing risk of cardiotoxicity in high risk pts undergoing anthracycline chemotherapy, 18% absolute risk reduction with Sacubitril-Valsartan vs placebo. Dr. Marcely Gimenes Bonatto shares results of SARAH trial https://t.co/HcstcCMebO
0
0
5
In this award-winning presentation at the @mr_linac meeting, I have shown why I believe the future of RT will involve the use of mid-treatment functional #MRI #DWI to identify areas of radioresistance and guide biologically adapted RT strategies. @Sunnybrook @UofTDRO
The amazing @UofTDRO @Sunnybrook #superstar fellow @DMoorePalhares giving his award winning talk on monitoring radiologic biomarkers of response in GBM patients at the @mr_linac annual meeting
9
10
65
How do we build a new generation of safer and more active ADCs for treating cancer? 👉By understanding how they actually work (and stop working) In this @CD_AACR review, we retrace 40 years of ADC development, highlighting key lessons learned. 🧵 below https://t.co/p2Wafhwk8z
7
59
191
Celebrating a significant milestone in immunology. Don’t miss the chance to delve into the latest advancements and future directions in T-cell receptor biology. 40th Anniversary: T-Cell Receptor Symposium
immunology.utoronto.ca
0
0
2
Congrats @DMoorePalhares
Our ph1 trial on MR-guided focused US for radiosensitization is out @RadiotherapyOn1 - 11 HN cancer pts - FUS + curative or palliative RT - Treatment was safe - Sustained complete responses observed Great work by Dr Czarnota Lab and RT team @Sunnybrook
https://t.co/bHQ7rr3JEZ
0
0
2
Fantastic presentation by the star Dr. @StephanieLheur5 Gynecology Oncology at #BestofASCO Toronto! 🌟 #GynOnc #ASCO2024
0
0
7
Congrats to our colleagues from Medical Gynecology Princess Margaret Cancer Centre for their poster presentations at ASCO 2024!
0
2
14